Clinical significance of ≥ 50% PD‐L1 expression with the SP263 monoclonal antibody in non‐small cell lung cancer patients

Clinical significance of ≥ 50% PD‐L1 expression with the SP263 monoclonal antibody in non‐small cell lung cancer patients

Background PD‐L1 expression in tumor cells has been associated with the efficacy of immune checkpoint inhibitors in non‐small cell lung cancer (NSCLC). The aim of this study was to explore correlations between smoking, genetic profiles, patient outcomes, and PD‐L1 expression in NSCLC. Methods PD‐L1...

Full description

Bibliographic Details
Main Authors: Wenbin Li, Peng Song, Lei Guo, Xiuyun Liu, Changyuan Guo, Jianming Ying, Shugeng Gao
Format: Article
Language:English
Published: Wiley 2019-02-01
Series:Thoracic Cancer
Subjects:
Driver mutation
non‐small cell lung cancer
programmed death ligand 1
smoking
Online Access:https://doi.org/10.1111/1759-7714.12929

Internet

https://doi.org/10.1111/1759-7714.12929

Similar Items